Effect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 Studies

April 2021 | Volume 20 | Issue 4 | Original Article | 394 | Copyright © April 2021

Published online March 22, 2021

Melinda J. Gooderham MD,a Boni Elewski MD,b Matthias Augustin MD,c Lars Iversen MD,d Hideshi Torii MD,e Russel Burge PhD,f,g Kyoungah See PhD,h Gaia Gallo MD,i William J. Eastman MD,j Missy McKean-Matthews MS,k Peter Foley MDl

^aDepartment of Medicine, Queens University and SKiN Centre for Dermatology, Peterborough, Ontario, Canada
^bDepartment of Dermatology, University of Alabama at Birmingham, Birmingham, AL
^cInstitute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
^dDepartment of Dermatology, Aarhus University Hospital, Aarhus, Denmark
^eDivision of Dermatology, Tokyo Yamate Medical Center, Tokyo, Japan
^fGlobal Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN
^gDivision of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, OH
^hDepartment of Statistical Science, Eli Lilly and Company, Indianapolis, IN
ⁱGlobal Medical Affairs, Eli Lilly and Company, Indianapolis, IN
^jUS Medical Affairs, Eli Lilly and Company, Indianapolis, IN
^kBiostatistics Department, Syneos Health, Morrisville, NC
^lDepartment of Medicine, The University of Melbourne, St. Vincent’s Hospital Melbourne and Probity Medical Research, Skin Health Institute, Melbourne, VIC, Australia